Hello youre watching r. T. International im Rosana Lockwood thank you for joining us. Recently unsealed Court Documents reveal that a u. S. Pharmaceuticals company conspired to aggressively push its opioid painkillers screenshots of email correspondence published in a multi district opioid lawsuit have led to accusations the purge you farmer caused americas biggest drug epidemic the company is also accused of downplaying the risks of addiction this led to doctors prescribing its pills to patients even with only minor pains with further details his caleb moore and. Usa is in the midst of an ongoing Opioid Epidemic. In the. In response to the Opioid Epidemic 48 different us states have taken action against produce pharma a drug manufacturer owned by the Sackler Family now even the company itself admits that those affected should get help as soon as possible while purdie farmer is prepared to defend itself vigorously in the opioids a geisha the company has made clear that it sees little g
At how a figurehead of the opposition honed his skills abroad. Also pakistans Prime Minister warns of a looming direct military confrontation with india over kashmir it comes as india says its ready for talks with pakistan but only in an atmosphere for you violence. Hello youre watching r. T. International im rosana locoed welcome to the program. Recently unsealed Court Documents reveal that a Us Pharmaceutical Company conspired to aggressively push its opioid painkillers screenshots of email correspondence published in a multi district opioid lawsuit have led to accusations that purge you pharma calls americas biggest drug epidemic the company is also accused of downplaying the risks of addiction this led to doctors prescribing its pills to patients even with only minor pains with further details his kelly. The usa is in the midst of an ongoing Opioid Epidemic. With the. In response to the Opioid Epidemic 48 different us states have taken action against produce pharma a drug manufactu
Play. I want to thank allen and pew for hosting this meeting, for organizing the publishing of the special supplement and of course to mr. Gottlieb for his remarks at the beginning of the day. So the focus of this final panel today is the fact that in certain high profile cases manufacturers have released incorrect or incomplete information into the market that was directly counter to the information, the contemporaneous information the fda had. They noted that selective publication of Clinical Trial results has in the past created a misleading picture of the safety and efficacy of a product with negative implications for Public Health. And as a the practice now still stands, manufactures have wide latitude to publicly characterize data that were submitted to the fda without much risk that the fda will correct the record. I think were going to try to talk a little bit about in the next hour is, you know, in these cases does the fda have a Public Health or an ethical responsibility to c
[ is distinct conversations ]. And live here this morning on c spann span 3, a discussion about transparency and oversight at the food and Drug Administration. Well be hearing from dr. Scott gottlieb starting off the conference. Introductions under way. Efforts to pass and implement the food safety modernization act, focus on medical devices, especially the potential of using the unique device identifier to improve monitoring devices throughout the product lifecycle. We have successfully worked on products 10 to courage innovation particularly around antibiotics and 10 to sure appropriate use of them. We focused on drug safety and transparency in the supply chain and especially on the safety of compounded drugs. Among other things, pew submitted transparency to the task force back in 2010 if the. They touch on some of the topics well be discussing today. Reading the background papers for todays meet regular mind med of a meeting we convened in a room directly above of us here a few yea
Thank you very much, josh, for that very nice introduction. I am aaron khere to introduce te final panel of the day that relates to another important set of Public Health functions, that Greater Transparency about information and regulatory decisions about the fda can play. I want to thank allen and pew for hosting this meeting, for organizing the publishing of the special supplement and of course to mr. Gottlieb for his remarks at the beginning of the day. So the focus of this final panel today is the fact that in certain high profile cases manufacturers have released incorrect or incomplete information into the market that was directly counter to the information, the contemporaneous information the fda had. They noted that selective publication of Clinical Trial results has in the past created a misleading picture of the safety and efficacy of a product with negative implications for Public Health. And as a the practice now still stands, manufactures have wide latitude to publicly ch